Володимир Володимирович Тутук
Володимир Володимирович Тутук has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Viktoriia Nazarkina
Національний фармацевтичний університет
3 shared publications Вікторія Миколаївна Назаркіна
2 shared publications- Наталія Сліпцова
Donetsk National Medical University, Ukraine
2 shared publications - A. S. Nemchenko
Bohomolets National Medical University, Kyiv
1 shared publication - Kairat Zhakipbekov
Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
1 shared publication - M. V. Podgaina
National University of Pharmacy, Kharkiv
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 110 (2) , 71-79
The study of the state and problems of pharmaceutical provision of orphan patients with medicines under managed entry agreements
Aim. To conduct a comprehensive study of the state and problems of providing orphan patients with innovative medicines purchased under managed entry agreements (MEA). Materials and methods. The analysis, generalization, and systematization of regulatory and legal acts, scientific publications, analytical and reporting data, information from the official websites of authorized bodies (the Ministry of Health of Ukraine, the central procurement organization SE “Medical Procurement of Ukraine,” State Expert Center of the Ministry of Health of Ukraine) and the “Prozorro” electronic procurement system regarding the purchase of orphan drugs under the terms of MEA were carried out. Results. The analysis of global experience has shown that MEAs (financial or clinical outcome-based) are used to expand access to innovative high-cost medicines both at the state level and for individual patients. According to the results of the studies conducted it has been found that as of September 2025, 23 names of drugs (17 INNs) are purchased in Ukraine under the conditions of MEA; among them, 13 INNs are for the treatment of rare diseases (mucopolysaccharidosis, Fabry disease, Gaucher disease, hemophilia A, primary (congenital) immunodeficiencies, spinal muscular atrophy (SMA)). All these medicines have previously undergone a state health technology assessment (HTA), including a comparative evaluation of their effectiveness, safety, and impact on the budget, and have been recognized as the optimal option for providing therapy for rare diseases. The analysis of “Prozorro” data shows that some medicines were purchased in a decentralized manner prior to the signing of the MEA. Currently, due to changes in the legislation, a transparent multi-level MEA mechanism is being created with the possibility of attracting various sources of funding, which will increase the effectiveness, targeting, and availability of pharmaceutical care. Conclusions. It has been proven that MEAs (also known as risk-sharing agreements) are a promising direction for improving the system of pharmaceutical provision for orphan patients who require continuous, high-cost treatment. The flexibility of the terms of MEAs makes it possible to expand the patients’ access to medicines, use rationally the limited financial resources, and collect real data on the clinical effectiveness of medicines. Key problems in the procurement of medicines under MEAs, such as insufficient transparency of the terms of agreements, lack of a patient registry, and a limited analytical base for evaluating clinical outcomes, have been identified.
- 8 December 2025
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 110 (2) , 71-79
Open AccessThe study of the state and problems of pharmaceutical provision of orphan patients with medicines under managed entry agreements
Aim. To conduct a comprehensive study of the state and problems of providing orphan patients with innovative medicines purchased under managed entry agreements (MEA). Materials and methods. The analysis, generalization, and systematization of regulatory and legal acts, scientific publications, analytical and reporting data, information from the official websites of authorized bodies (the Ministry of Health of Ukraine, the central procurement organization SE “Medical Procurement of Ukraine,” State Expert Center of the Ministry of Health of Ukraine) and the “Prozorro” electronic procurement system regarding the purchase of orphan drugs under the terms of MEA were carried out. Results. The analysis of global experience has shown that MEAs (financial or clinical outcome-based) are used to expand access to innovative high-cost medicines both at the state level and for individual patients. According to the results of the studies conducted it has been found that as of September 2025, 23 names of drugs (17 INNs) are purchased in Ukraine under the conditions of MEA; among them, 13 INNs are for the treatment of rare diseases (mucopolysaccharidosis, Fabry disease, Gaucher disease, hemophilia A, primary (congenital) immunodeficiencies, spinal muscular atrophy (SMA)). All these medicines have previously undergone a state health technology assessment (HTA), including a comparative evaluation of their effectiveness, safety, and impact on the budget, and have been recognized as the optimal option for providing therapy for rare diseases. The analysis of “Prozorro” data shows that some medicines were purchased in a decentralized manner prior to the signing of the MEA. Currently, due to changes in the legislation, a transparent multi-level MEA mechanism is being created with the possibility of attracting various sources of funding, which will increase the effectiveness, targeting, and availability of pharmaceutical care. Conclusions. It has been proven that MEAs (also known as risk-sharing agreements) are a promising direction for improving the system of pharmaceutical provision for orphan patients who require continuous, high-cost treatment. The flexibility of the terms of MEAs makes it possible to expand the patients’ access to medicines, use rationally the limited financial resources, and collect real data on the clinical effectiveness of medicines. Key problems in the procurement of medicines under MEAs, such as insufficient transparency of the terms of agreements, lack of a patient registry, and a limited analytical base for evaluating clinical outcomes, have been identified.
- Open Access
- 31 October 2023
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 5(45),p. 99-108
Assessment of medical technologies in the formation of government programs to assist patients with rare metabolic diseases
The aim: carrying out an assessment of the technologies of nutritional and pharmacological therapy of phenylketonuria (PKU) to justify a set of measures for the implementation of the government program to support patients with rare diseases (RD). Materials and methods: scientific publications, regulatory acts, treatment protocols, statistical data, epidemiological indicators, results of patient questionnaires, marketing information, data from the electronic procurement system "ProZorro" were used in the research process. The research was conducted using the methodology of health technology assessment (HTA), methods of marketing analysis, questionnaire survey, document analysis, comparison, systematization and generalization of data. Research results. An analysis of the evaluation of modern approaches to the treatment of hereditary rare metabolic disease (PKU) was carried out. According to clinical protocols, the main technology for the treatment of PKU is nutritional therapy - a diet (diet-for-life) with restriction of the use of phenylalanine (Phe) and the use of food products for special medical purposes (Special low protein foods for phenylketonuria - SLPF-PKU). Innovative drugs "Kuvan" and "Palynziq" are recommended in the case of atypical PKU. For RD, specific and innovative cost-effective medical technologies (MT) are usually used, which have insufficient evidence due to limited experience, low availability, and small patient populations. Centralized procurement and managed entry agreements (MEA) make it possible to expand the availability of MT to patients and obtain real data on their safety and effectiveness. Integration into the global information space, participation in international projects, joint clinical assessment (JCA) in accordance with Regulation (EU) 2021/2282 on HTA, cooperation with Orphanet, EURORDIS, other professional and patient organizations are extremely important. The key components of HTA for RD are socio-economic and organizational and legal aspects, in particular the special status of MT, which provides certain preferences. The foreign experience of providing orphan patients (in particular, reimbursement) is summarized. The legal framework for RD is systematized. Based on the results of the analysis of PKU prevalence indicators, modelling and budget impact calculations were carried out, considering that SLPF-PKU products are purchased from local budgets. An analysis of prescriptions, assortment, and prices of SLPF-PKU was carried out using data from the ProZorro procurement system. A survey of 156 patients with PKU made it possible to identify unmet needs and formulate recommendations for expanding the SLPF-PKU food basket. Conclusions: Conducting the HTA made it possible to identify key problems, as well as to justify a set of measures for the development and implementation of the government program to support patients with rare diseases, based on the obtained results
- 31 October 2023
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 5(45),p. 99-108
Open AccessAssessment of medical technologies in the formation of government programs to assist patients with rare metabolic diseases
The aim: carrying out an assessment of the technologies of nutritional and pharmacological therapy of phenylketonuria (PKU) to justify a set of measures for the implementation of the government program to support patients with rare diseases (RD). Materials and methods: scientific publications, regulatory acts, treatment protocols, statistical data, epidemiological indicators, results of patient questionnaires, marketing information, data from the electronic procurement system "ProZorro" were used in the research process. The research was conducted using the methodology of health technology assessment (HTA), methods of marketing analysis, questionnaire survey, document analysis, comparison, systematization and generalization of data. Research results. An analysis of the evaluation of modern approaches to the treatment of hereditary rare metabolic disease (PKU) was carried out. According to clinical protocols, the main technology for the treatment of PKU is nutritional therapy - a diet (diet-for-life) with restriction of the use of phenylalanine (Phe) and the use of food products for special medical purposes (Special low protein foods for phenylketonuria - SLPF-PKU). Innovative drugs "Kuvan" and "Palynziq" are recommended in the case of atypical PKU. For RD, specific and innovative cost-effective medical technologies (MT) are usually used, which have insufficient evidence due to limited experience, low availability, and small patient populations. Centralized procurement and managed entry agreements (MEA) make it possible to expand the availability of MT to patients and obtain real data on their safety and effectiveness. Integration into the global information space, participation in international projects, joint clinical assessment (JCA) in accordance with Regulation (EU) 2021/2282 on HTA, cooperation with Orphanet, EURORDIS, other professional and patient organizations are extremely important. The key components of HTA for RD are socio-economic and organizational and legal aspects, in particular the special status of MT, which provides certain preferences. The foreign experience of providing orphan patients (in particular, reimbursement) is summarized. The legal framework for RD is systematized. Based on the results of the analysis of PKU prevalence indicators, modelling and budget impact calculations were carried out, considering that SLPF-PKU products are purchased from local budgets. An analysis of prescriptions, assortment, and prices of SLPF-PKU was carried out using data from the ProZorro procurement system. A survey of 156 patients with PKU made it possible to identify unmet needs and formulate recommendations for expanding the SLPF-PKU food basket. Conclusions: Conducting the HTA made it possible to identify key problems, as well as to justify a set of measures for the development and implementation of the government program to support patients with rare diseases, based on the obtained results
- Open Access
- 18 September 2023
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 3,p. 75-83
ОБҐРУНТУВАННЯ НАПРЯМІВ ПІДВИЩЕННЯ ЕФЕКТИВНОСТІ ФАРМАЦЕВТИЧНОГО ЗАБЕЗПЕЧЕННЯ ХВОРИХ НА ФЕНІЛКЕТОНУРІЮ
Фенілкетонурія (ФКУ) належить до рідкісних метаболічних захворювань, для пацієнтів життєво необхідним є застосування продуктів спеціального медичного харчування (СМХ) для досягнення метаболічного контролю. Основними проблемами є складність дотримання жорсткої дієти у дітей та підлітків, низька цінова доступність продуктів СМХ, дефіцит бюджетних коштів. Маркетинговий аналіз асортименту й цін на продукти СМХ проведено на підставі вивчення прайс-листів дистриб’юторів і пропозицій онлайн-магазинів. Проведено аналіз тендерної документації та закупівельних цін на продукти СМХ за укладеними договорами за 2022-2023 р., що опубліковані в електронній системі «Прозорро». Аналіз медико-технічних вимог для закупівлі продуктів СМХ дозволив визначити ключові критерії, які вказані в тендерній документації. Аналіз показав, що закупівлі підлягають переважно порошкові амінокислотні суміші (АКС) іноземного виробництва, що призначаються лікарями індивідуально залежно від віку пацієнта та особливостей перебігу захворювання. Проведено онлайн-опитування пацієнтів, хворих на ФКУ (або членів їхніх родин, що доглядають за ними) за розробленою анкетою з використанням goggle-форм (n = 156). Це дозволило визначити споживацькі переваги і попит на продукти СМХ різних груп (макарони, хліб, кондитерські вироби тощо). Науково обґрунтовано рецептуру та технологію низькобілкових продуктів СМХ для хворих на ФКУ. Також у процесі досліджень було розроблено склад і технологію таблеток, що містять комбінацію великих нейтральних амінокислот (LNAA). Доведено економічну ефективність виробництва продуктів СМХ та доцільність їх закупівлі для забезпечення потреб пацієнтів з ФКУ в межах регіональних програм.
- 18 September 2023
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 3,p. 75-83
Open AccessОБҐРУНТУВАННЯ НАПРЯМІВ ПІДВИЩЕННЯ ЕФЕКТИВНОСТІ ФАРМАЦЕВТИЧНОГО ЗАБЕЗПЕЧЕННЯ ХВОРИХ НА ФЕНІЛКЕТОНУРІЮ
Фенілкетонурія (ФКУ) належить до рідкісних метаболічних захворювань, для пацієнтів життєво необхідним є застосування продуктів спеціального медичного харчування (СМХ) для досягнення метаболічного контролю. Основними проблемами є складність дотримання жорсткої дієти у дітей та підлітків, низька цінова доступність продуктів СМХ, дефіцит бюджетних коштів. Маркетинговий аналіз асортименту й цін на продукти СМХ проведено на підставі вивчення прайс-листів дистриб’юторів і пропозицій онлайн-магазинів. Проведено аналіз тендерної документації та закупівельних цін на продукти СМХ за укладеними договорами за 2022-2023 р., що опубліковані в електронній системі «Прозорро». Аналіз медико-технічних вимог для закупівлі продуктів СМХ дозволив визначити ключові критерії, які вказані в тендерній документації. Аналіз показав, що закупівлі підлягають переважно порошкові амінокислотні суміші (АКС) іноземного виробництва, що призначаються лікарями індивідуально залежно від віку пацієнта та особливостей перебігу захворювання. Проведено онлайн-опитування пацієнтів, хворих на ФКУ (або членів їхніх родин, що доглядають за ними) за розробленою анкетою з використанням goggle-форм (n = 156). Це дозволило визначити споживацькі переваги і попит на продукти СМХ різних груп (макарони, хліб, кондитерські вироби тощо). Науково обґрунтовано рецептуру та технологію низькобілкових продуктів СМХ для хворих на ФКУ. Також у процесі досліджень було розроблено склад і технологію таблеток, що містять комбінацію великих нейтральних амінокислот (LNAA). Доведено економічну ефективність виробництва продуктів СМХ та доцільність їх закупівлі для забезпечення потреб пацієнтів з ФКУ в межах регіональних програм.
- Open Access
- 19 May 2023
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 9 (1) , 30-38
Analysis of the availability of health technologies for the treatment of phenylketonuria in Ukraine and the world
Phenylketonuria (PKU) is a rare (orphan) disease characterized by a severe, chronic, progressive course. Patients' quality of life depends on timely detection (screening) and proper treatment - the use of special medical food products, and therefore, their availability and affordability. The goal (objective) of the study is to analyze the available health technologies for the treatment of PKU in Ukraine and the world. Materials and methods. Research objects: scientific publications, guidelines, statistical data, marketing information. Methods: analysis, comparison, generalization, system analysis. Results of the research. Guidelines and protocols for the treatment of patients with PKU/HFA define a diet as a key component, taking into account the age and features of the course of the disease. The analysis of providing patients with PKU with special medical food products in different countries shows significant differences in the approaches to their assignment and reimbursement. The quantity, availability, range and composition of these products vary significantly. In the UK, they are included in the national formulary, are available on prescription and are subject to reimbursement. In Ukraine, local authorities provide PKU patients with special medical food products by procurement through the ProZorro electronic system in accordance with the calculated need. In the domestic market, there is a wide range of specialized products for patients with PKU/HFA, mainly of imported production, which have a high cost and, accordingly, low accessibility for the population. Conclusions. The introduction of reference centers and extended neonatal screening, the creation of a register of such patients, the development of domestic production of products for PKU/HPA, and the creation of effective procurement and reimbursement mechanisms will contribute to increasing the effectiveness of treatment, the quality and life expectancy of patients.
- 19 May 2023
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 9 (1) , 30-38
Open AccessAnalysis of the availability of health technologies for the treatment of phenylketonuria in Ukraine and the world
Phenylketonuria (PKU) is a rare (orphan) disease characterized by a severe, chronic, progressive course. Patients' quality of life depends on timely detection (screening) and proper treatment - the use of special medical food products, and therefore, their availability and affordability. The goal (objective) of the study is to analyze the available health technologies for the treatment of PKU in Ukraine and the world. Materials and methods. Research objects: scientific publications, guidelines, statistical data, marketing information. Methods: analysis, comparison, generalization, system analysis. Results of the research. Guidelines and protocols for the treatment of patients with PKU/HFA define a diet as a key component, taking into account the age and features of the course of the disease. The analysis of providing patients with PKU with special medical food products in different countries shows significant differences in the approaches to their assignment and reimbursement. The quantity, availability, range and composition of these products vary significantly. In the UK, they are included in the national formulary, are available on prescription and are subject to reimbursement. In Ukraine, local authorities provide PKU patients with special medical food products by procurement through the ProZorro electronic system in accordance with the calculated need. In the domestic market, there is a wide range of specialized products for patients with PKU/HFA, mainly of imported production, which have a high cost and, accordingly, low accessibility for the population. Conclusions. The introduction of reference centers and extended neonatal screening, the creation of a register of such patients, the development of domestic production of products for PKU/HPA, and the creation of effective procurement and reimbursement mechanisms will contribute to increasing the effectiveness of treatment, the quality and life expectancy of patients.
- Open Access
- 1 January 2023
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 1,p. 50-55
ANALYSIS OF THE SUPPLY OF PRODUCTS FOR SPECIAL MEDICAL PURPOSES TO CHILDREN WITH PHENYLKETONURIA
Phenylketonuria (PKU) refers to hereditary disorders of amino acid metabolism, which requires long-term, high-cost treatment (use of special medical nutrition – SMN). The article is devoted to the analysis of the state of providing children with PKU with the necessary products of SMN in accordance with the requirements of current legislation in terms of price and physical availability. Significant differences in approaches to providing patients with PKU with SMN products, their classification and assortment, specifics of prescribing by physicians and reimbursement in different countries were identified. It was found that doctors most often prescribe powdered amino acid mixtures (AAM) (73%) of foreign production (Great Britain, Italy, Germany, Spain) at a price from UAH 1,000 to 7,000 per package (500 g jar). The main criteria for the selection of SMH by doctors are the optimal protein content in a product unit for a certain age group, a balanced amount of nutrients and the lowest cost of 1.0 g of protein. The analysis showed that the amount of protein in 100 g of the product varies from 2.0 to 83.3, the cost of 1 g of protein is from 13.50 to 109.00 UAH. In Ukraine, according to the legislation, such products should be classified as SMN and, accordingly, could be taxed at a preferential VAT rate of 7% instead of 20%. This would make it possible to significantly increase the availability of SMN for patients and reduce the burden on the budget, which is confirmed by the relevant forecast calculations. Thus, a consistent comprehensive state policy in the field of providing patients with orphan metabolic diseases, in particular PKU/HPA, aimed at providing them with safe and affordable SMN products (in particular due to the development of domestic production and the introduction of preferential taxation), will increase the duration and quality of life of such patients. Фенілкетонурія (ФКУ) відноситься до спадкових порушень обміну амінокислот, що потребує тривалого високовартісного лікування (вживання спеціального медичного харчування – СМХ). Мета статті – провести аналіз стану забезпечення дітей, хворих на ФКУ, необхідними продуктами спеціального медичного харчування (СМХ) відповідно до вимог чинного законодавства в аспекті цінової та фізичної доступності. Встановлено значні відмінності у підходах щодо забезпечення хворих на ФКУ продуктами СМХ, їх класифікації та асортименту, особливостей призначення та відшкодування вартості у різних країнах. Встановлено, що лікарями призначаються переважно порошкові амінокислотні суміші (АКС) (73%) іноземного виробництва (Великої Британії, Італії, Німеччини, Іспанії) за ціною від 1 до 7 тис. грн за упаковку (банку 500 г). Основними критеріями підбору СМХ лікарями є оптимальний для певної вікової групи вміст білка в одиниці продукту, збалансована кількість нутрієнтів та найменша вартість 1,0 г білка. Аналіз показав, що кількість білка у 100 г продукту коливається від 2,0 до 83,3, вартість 1 г білку становить від 13,50 до 109,00 грн. В Україні відповідно до законодавства такі продукти мали б бути класифіковані як СМХ та відповідно могли б оподатковуватися за пільговою ставкою ПДВ 7% замість 20%. Це дозволило б суттєво підвищити доступність СМХ для пацієнтів і зменшити навантаження на бюджет, що підтверджено відповідними прогнозними розрахунками. Таким чином, послідовна комплексна державна політика в галузі забезпечення хворих, що страждають на орфанні метаболічні захворювання, зокрема ФКУ/ГФА, спрямована на їх забезпечення безпечними і доступними продуктами СМХ (зокрема за рахунок розвитку вітчизняного виробництва і упровадження пільгового оподаткування), дозволить підвищити тривалість і якість життя таких пацієнтів.
- 1 January 2023
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 1,p. 50-55
Open AccessANALYSIS OF THE SUPPLY OF PRODUCTS FOR SPECIAL MEDICAL PURPOSES TO CHILDREN WITH PHENYLKETONURIA
Phenylketonuria (PKU) refers to hereditary disorders of amino acid metabolism, which requires long-term, high-cost treatment (use of special medical nutrition – SMN). The article is devoted to the analysis of the state of providing children with PKU with the necessary products of SMN in accordance with the requirements of current legislation in terms of price and physical availability. Significant differences in approaches to providing patients with PKU with SMN products, their classification and assortment, specifics of prescribing by physicians and reimbursement in different countries were identified. It was found that doctors most often prescribe powdered amino acid mixtures (AAM) (73%) of foreign production (Great Britain, Italy, Germany, Spain) at a price from UAH 1,000 to 7,000 per package (500 g jar). The main criteria for the selection of SMH by doctors are the optimal protein content in a product unit for a certain age group, a balanced amount of nutrients and the lowest cost of 1.0 g of protein. The analysis showed that the amount of protein in 100 g of the product varies from 2.0 to 83.3, the cost of 1 g of protein is from 13.50 to 109.00 UAH. In Ukraine, according to the legislation, such products should be classified as SMN and, accordingly, could be taxed at a preferential VAT rate of 7% instead of 20%. This would make it possible to significantly increase the availability of SMN for patients and reduce the burden on the budget, which is confirmed by the relevant forecast calculations. Thus, a consistent comprehensive state policy in the field of providing patients with orphan metabolic diseases, in particular PKU/HPA, aimed at providing them with safe and affordable SMN products (in particular due to the development of domestic production and the introduction of preferential taxation), will increase the duration and quality of life of such patients. Фенілкетонурія (ФКУ) відноситься до спадкових порушень обміну амінокислот, що потребує тривалого високовартісного лікування (вживання спеціального медичного харчування – СМХ). Мета статті – провести аналіз стану забезпечення дітей, хворих на ФКУ, необхідними продуктами спеціального медичного харчування (СМХ) відповідно до вимог чинного законодавства в аспекті цінової та фізичної доступності. Встановлено значні відмінності у підходах щодо забезпечення хворих на ФКУ продуктами СМХ, їх класифікації та асортименту, особливостей призначення та відшкодування вартості у різних країнах. Встановлено, що лікарями призначаються переважно порошкові амінокислотні суміші (АКС) (73%) іноземного виробництва (Великої Британії, Італії, Німеччини, Іспанії) за ціною від 1 до 7 тис. грн за упаковку (банку 500 г). Основними критеріями підбору СМХ лікарями є оптимальний для певної вікової групи вміст білка в одиниці продукту, збалансована кількість нутрієнтів та найменша вартість 1,0 г білка. Аналіз показав, що кількість білка у 100 г продукту коливається від 2,0 до 83,3, вартість 1 г білку становить від 13,50 до 109,00 грн. В Україні відповідно до законодавства такі продукти мали б бути класифіковані як СМХ та відповідно могли б оподатковуватися за пільговою ставкою ПДВ 7% замість 20%. Це дозволило б суттєво підвищити доступність СМХ для пацієнтів і зменшити навантаження на бюджет, що підтверджено відповідними прогнозними розрахунками. Таким чином, послідовна комплексна державна політика в галузі забезпечення хворих, що страждають на орфанні метаболічні захворювання, зокрема ФКУ/ГФА, спрямована на їх забезпечення безпечними і доступними продуктами СМХ (зокрема за рахунок розвитку вітчизняного виробництва і упровадження пільгового оподаткування), дозволить підвищити тривалість і якість життя таких пацієнтів.
- Open Access
- 20 December 2021
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 6,p. 28-36
Analysis of the number of registered patients whis rare diseases in some regions of Ukraine
Rare (orphan) diseases (RD) are a global priority for health systems. In Europe, including Ukraine, the disease is considered rare with a prevalence of 1 patient per 2,000 population. To date, by the orphanet data, 6,172 unique rare diseases have been discovered. An important issue today is the understanding and analysis of data on the prevalence of RD in Ukraine, which will effectively plan the need for therapy and predict its cost. Aim of the investigation was to analyze the available data on the of the registered cases of orphan diseases among children and adults in all Ukraine’s regions and determining the share of each disease in the overall structure in terms of age group of patients. The object of the in vestigation are data of the Department of Statistics of the Ministry of Health on the cases of rare diseases, that were registered in Ukraine as of January 2020 and Medical Genetics Center’s data. The study was conducted using informative methods of analysis (collection and data processing), systematization and generalization, mathematical and statistical calculations. According to the Сenter’s of Medical Statistics of the Ministry of Health data the total number of registered patients was 10786 patients, of whom children accounted for 54%. Among given diseases the largest proportion of patients had been registered with a diagnosis of «juvenile rheumatoid arthritis» – 2,291 patients, most of whom, almost 80%, are children. Among 18 rare diseases, 11%, were registered only among pediatric patients: Pump's disease, Fabri's disease. It has been established that Kyiv, Poltava, Dnipro, Ivano-Frankivsk and Kharkiv regions had been characterized by the highest total number of orphan patients. Regions with the lowestregistered number of orphan patients – are Luhansk, Lviv, Kherson, Sumyand Volyn. There was no information on registered RDs in Chernivtsi, Odesa, Zakarpattia regions and Kyiv city from the Center for Medical Statistics of the Ministry of Health, but it was indicated the cases of four RDs in Odessa region and Kyiv city by newborn screening program in 2020, that has shown problems in the collection, centralization and coordination of the statistic information of RDs and needs to be resolved in the future at the state and regional levels.
- 20 December 2021
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 6,p. 28-36
Open AccessAnalysis of the number of registered patients whis rare diseases in some regions of Ukraine
Rare (orphan) diseases (RD) are a global priority for health systems. In Europe, including Ukraine, the disease is considered rare with a prevalence of 1 patient per 2,000 population. To date, by the orphanet data, 6,172 unique rare diseases have been discovered. An important issue today is the understanding and analysis of data on the prevalence of RD in Ukraine, which will effectively plan the need for therapy and predict its cost. Aim of the investigation was to analyze the available data on the of the registered cases of orphan diseases among children and adults in all Ukraine’s regions and determining the share of each disease in the overall structure in terms of age group of patients. The object of the in vestigation are data of the Department of Statistics of the Ministry of Health on the cases of rare diseases, that were registered in Ukraine as of January 2020 and Medical Genetics Center’s data. The study was conducted using informative methods of analysis (collection and data processing), systematization and generalization, mathematical and statistical calculations. According to the Сenter’s of Medical Statistics of the Ministry of Health data the total number of registered patients was 10786 patients, of whom children accounted for 54%. Among given diseases the largest proportion of patients had been registered with a diagnosis of «juvenile rheumatoid arthritis» – 2,291 patients, most of whom, almost 80%, are children. Among 18 rare diseases, 11%, were registered only among pediatric patients: Pump's disease, Fabri's disease. It has been established that Kyiv, Poltava, Dnipro, Ivano-Frankivsk and Kharkiv regions had been characterized by the highest total number of orphan patients. Regions with the lowestregistered number of orphan patients – are Luhansk, Lviv, Kherson, Sumyand Volyn. There was no information on registered RDs in Chernivtsi, Odesa, Zakarpattia regions and Kyiv city from the Center for Medical Statistics of the Ministry of Health, but it was indicated the cases of four RDs in Odessa region and Kyiv city by newborn screening program in 2020, that has shown problems in the collection, centralization and coordination of the statistic information of RDs and needs to be resolved in the future at the state and regional levels.